KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Receivables - Other (2018 - 2025)

Historic Receivables - Other for Takeda Pharmaceutical (TAK) over the last 8 years, with Q1 2025 value amounting to $380.5 million.

  • Takeda Pharmaceutical's Receivables - Other rose 75.75% to $380.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $380.5 million, marking a year-over-year increase of 75.75%. This contributed to the annual value of $381.1 million for FY2025, which is 179.65% down from last year.
  • Takeda Pharmaceutical's Receivables - Other amounted to $380.5 million in Q1 2025, which was up 75.75% from $377.6 million recorded in Q1 2024.
  • In the past 5 years, Takeda Pharmaceutical's Receivables - Other registered a high of $714.3 million during Q1 2021, and its lowest value of $377.6 million during Q1 2024.
  • Over the past 5 years, Takeda Pharmaceutical's median Receivables - Other value was $559.4 million (recorded in 2023), while the average stood at $542.5 million.
  • In the last 5 years, Takeda Pharmaceutical's Receivables - Other crashed by 3249.65% in 2024 and then skyrocketed by 75.75% in 2025.
  • Takeda Pharmaceutical's Receivables - Other (Quarter) stood at $714.3 million in 2021, then decreased by 4.68% to $680.9 million in 2022, then decreased by 17.84% to $559.4 million in 2023, then tumbled by 32.5% to $377.6 million in 2024, then rose by 0.76% to $380.5 million in 2025.
  • Its last three reported values are $380.5 million in Q1 2025, $377.6 million for Q1 2024, and $559.4 million during Q1 2023.